Ask AI
ProCE Banner Activity

Empowering NPs and PAs With Frontline Strategies to Recognize and Treat ATTR-CM

Clinical Thought

A concise, clinically focused overview of how to recognize and manage patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Red flags and diagnostic pathways are described and current treatment strategies are summarized, emphasizing early identification and disease-modifying therapy to improve outcomes.

Released: December 30, 2025

Continue Activity View Activity

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with the the Academy of Physician Associates in Cardiology (APAC).

ProCE Banner

Supporters

This activity is supported by an educational grant from Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals

Partners

Academy of Physician Associates in Cardiology (APAC)

ProCE Banner

Target Audience

This activity is intended for cardiology-focused nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the burden, signs, and clinical manifestations of ATTR-CM to facilitate prompt, precise, and thorough diagnosis

  • Formulate individualized treatment strategies using novel disease-modifying therapies to improve patient outcomes

  • Empower patients to understand their ATTR-CM diagnosis and the clinical rationale for disease-modifying therapies, addressing concerns about safety and progression while providing practical strategies to support treatment adherence through shared decision-making

Disclosure

Primary Author

Jill S. Waldron, APRN, GNP-BC: consultant/advisor/speaker: Alnylam, Bridge Bio.